The Bristol Myers Squibb Q3 2026 results are a test of whether a drug maker can replace revenue faster than it loses it. Bristol Myers Squibb reported third-quarter revenue of $13.1 billion, up 7%, raised its 2026 revenue forecast to $49.75 billion to $50.25 billion and said newer products are carrying growth, while a $1.6 billion acquired-research charge pulled earnings per share down 17% to $1.35, according to press reports. This business analysis looks at the portfolio mix, guidance, the Eliquis exclusivity challenge, cash and capital spending, and a conflict in reports on earnings guidance. It offers no investment view.
Bristol Myers Squibb Q3 2026 results: financial takeaways
- Revenue $13.1 billion (+7%); Growth Portfolio $7.7 billion (+12%); Legacy Portfolio $5.4 billion (+1%).
- Non-GAAP EPS $1.35 (-17%), with a $0.58 per share impact from a $1.6 billion acquired research and licensing charge.
- 2026 revenue guidance raised to $49.75 billion to $50.25 billion from $49 billion to $50 billion.
- Reports say 2026 EPS guidance was lowered to $6.35 to $6.55 from $6.75 to $7.00; one summary says raised, and we could not reach a primary release.
- Eliquis faces European exclusivity loss in the fourth quarter and a $1.5 billion to $2 billion step-down is expected in 2027.
Portfolio mix in the Bristol Myers Squibb Q3 2026 results
By our own calculation, the Growth Portfolio contributed about 59% of quarterly revenue ($7.7 billion of $13.1 billion) and the Legacy Portfolio about 41%. The Growth Portfolio grew 12% against 1% for the Legacy Portfolio. Individual products include Breyanzi at $526 million (+48%), Camzyos at $420 million (+42%), Opdivo Qvantig at $334 million (+28% sequentially) and Cobenfy at $57 million (+33%). Eliquis, at about $4.7 billion (+26%), remains the largest single contributor. Regulatory filings are posted by the US Securities and Exchange Commission.
The guidance puzzle in the Bristol Myers Squibb Q3 2026 results
Revenue guidance is clear: raised. Earnings guidance is not. Two summaries and the brief we received say the 2026 adjusted EPS range was lowered to $6.35 to $6.55 from $6.75 to $7.00 because of the $0.58 per share charge, while one transcript summary used the word raised. By our own calculation, the old midpoint was $6.875 and the new one is $6.45, a reduction of about $0.43 or 6%, and adding $0.58 back to the new range gives roughly $6.93 to $7.13, which is at or above the old range. That arithmetic supports the lowered reading, but we could not verify it against a primary release.
The Eliquis challenge in the Bristol Myers Squibb Q3 2026 results
Eliquis is the company’s largest product. Management expects 2026 growth of 20% to 25%, a Legacy Portfolio decline of 3% to 5% and a $1.5 billion to $2 billion Eliquis step-down in 2027 as exclusivity ends in Europe. Management is also targeting $2 billion of efficiencies by the end of 2027. The central business question is whether the Growth Portfolio can grow fast enough to absorb the step-down, and the sources do not give a 2027 outlook.
Cash and capital spending in the Bristol Myers Squibb Q3 2026 results
The company had about $13 billion in cash and marketable securities and about $4.2 billion of operating cash flow in the quarter. It plans a $2.3 billion manufacturing campus in Houston and, through RayzeBio, more than $170 million for a radiopharmaceutical site in Indiana. The acquired-research charge of $1.6 billion shows that it is also buying pipeline assets. Chief executive Chris Boerner and chief financial officer David Elkins commented on the results. Company information is at bms.com.
Pipeline catalysts in the Bristol Myers Squibb Q3 2026 results
Catalysts include Phase 3 progression-free survival data for Zenbexus, which has accelerated approval in multiple myeloma, at the ASH meeting in December; milvexian and Sotyktu lupus data before year-end; and a target action date of 13 May 2027 for the investigational mezigdomide. Admilparant met its primary endpoint in idiopathic pulmonary fibrosis at 60 mg but not at 120 mg. Investigational drugs are not approved for these uses.
Market context from Acumen Research and Consulting
Acumen Research and Consulting’s Cancer Therapeutics Market report values the global market at USD 193.7 billion in 2024 and projects USD 381.5 billion by 2033, a CAGR of 7.9% for 2025 to 2033. North America was USD 71.7 billion in 2024, and Asia Pacific is projected to grow fastest at 8.8%. By our own calculation, the forecast roughly doubles the market over nine years. The report was published in April 2025 and covers oncology only.
Questions analysts may ask about the Bristol Myers Squibb Q3 2026 results
How large is the 2027 revenue gap after Eliquis? How quickly can the Growth Portfolio fill it? What acquisitions drove the charge? Will efficiency savings be enough? How will pricing policy affect the legacy brands? None is answered in the sources, and this article offers no investment view. See our industry insights.
Timeline of the Bristol Myers Squibb Q3 2026 results
- Late October 2026: results and raised revenue guidance.
- December 2026: ASH data for Zenbexus.
- 13 May 2027: mezigdomide target action date.
General background: patent cliffs in pharma
When a major medicine loses exclusivity, generic competition can reduce its sales sharply, so large drug makers plan years ahead to replace the revenue through new launches, acquisitions and cost reduction.
Our analysis of the Bristol Myers Squibb Q3 2026 results
In our assessment, the Bristol Myers Squibb Q3 2026 results show a transition that is working on the top line, with the newer portfolio now the majority of sales, but one that depends on pipeline delivery and cost savings to bridge the 2027 Eliquis step-down.
What is not disclosed in the Bristol Myers Squibb Q3 2026 results
- A primary company release confirming EPS guidance.
- 2027 outlook.
- Details of the acquisitions behind the charge.
Risks and caveats
This article relies on press reports and labelled calculations. It is news reporting and not investment advice.
What to watch next
- ASH data.
- Eliquis in Europe.
- Efficiency programme progress.
FAQ
Was guidance raised?
Revenue guidance was raised; EPS guidance was reportedly lowered.
Why did EPS fall?
A $1.6 billion acquired research and licensing charge.
What is the main risk?
The 2027 Eliquis step-down.
How we reported this: we relied on press reports of the results, public company and regulator pages and the Acumen Research and Consulting report cited above. We did not have a primary company release. Our calculations are labelled. Last updated 30 October 2026. This is news reporting and not advice.
